Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction (LVFR-AMI)

• Sponsor: Xiamen Cardiovascular Hospital, Xiamen University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04172168
• Collaborator: (none)
• Enrollment: 17,568
• Location: 1
• Anticipated Duration (Months): 122.9
• Patients Per Site Per Month: 142.9

Study Details

Study Description

Brief Summary

The Left Ventricular Free-wall Ruptrue (LVFR) is a serious complication caused high mortality.

Condition or Disease	Intervention/Treatment	Phase
Acute Myocardial Infarction	Diagnostic Test: Heart rupture

Detailed Description

The actual mortality of LVFR is close to 100%. Despite the mortality rate for LVFR has been decreasing with the development of reperfusion therapy, the serious complication remains a difficult challenge. The coronary anatomy distribution associated with LVFR has an interesting phenomenon. From the perspective of different coronary distribution, we can better known the risk factors related to LVFR.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 17568 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Clinical Characteristics of Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction
• Actual Study Start Date: Jan 1, 2011
• Actual Primary Completion Date: Dec 31, 2019
• Anticipated Study Completion Date: Mar 31, 2021

Arms and Interventions

Arm	Intervention/Treatment
Heart rupture Include left ventricular free-wall ruptrue after AMI	Diagnostic Test: Heart rupture; Left ventricular free-wall ruptrue after AMI
Non heart rupture AMI with non heart rupture

Outcome Measures

Primary Outcome Measures

1. Rate of heart ruputre [Mortality 30 days]

   Left Ventricular Free-wall Ruptrue

Secondary Outcome Measures

1. Rate of cardiogenic shock [Hospitalization 30 days]

   Cardiogenic shock After AMI

2. Rate of cardiac arrest [Hospitalization 30 days]

   Cardiac arrest After AMI

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)

Exclusion Criteria:

• Non-cardiovascular comorbidity for AMI

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Xiamen Cardiovascular Hospital Xiamen University	Xiamen	Fujian	China	361000

Sponsors and Collaborators

• Xiamen Cardiovascular Hospital, Xiamen University

Investigators

• Study Chair: Yan Wang, PhD, Cardiovascular Hospital, Xiamen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Yan Wang, President, Xiamen Cardiovascular Hospital, Xiamen University
• ClinicalTrials.gov Identifier: NCT04172168
• Other Study ID Numbers: 9215443689
• First Posted: Nov 21, 2019
• Last Update Posted: Apr 1, 2021
• Last Verified: Mar 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Yan Wang, President, Xiamen Cardiovascular Hospital, Xiamen University: Left Ventricular Free-wall Ruptrue; Acute myocardial infarction; Coronary angiography
• Additional relevant MeSH terms: Myocardial Infarction; Infarction

Study Results

No Results Posted as of Apr 1, 2021